2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
1256
Neoplasms
1074
Carcinoma, Non-Small-Cell Lung
874
Prostatic Neoplasms
714
Lung Neoplasms
596
Colorectal Neoplasms
590
Neoplasm Metastasis
452
Multiple Myeloma
432
Leukemia, Myeloid, Acute
423
Pancreatic Neoplasms
370
Ovarian Neoplasms
367
Melanoma
324
Carcinoma, Hepatocellular
299
Squamous Cell Carcinoma of Head and Neck
276
Brain Neoplasms
275
Recurrence
273
Stomach Neoplasms
245
Head and Neck Neoplasms
241
Glioblastoma
239
Carcinoma, Renal Cell
227
Lymphoma
226
Triple Negative Breast Neoplasms
225
Precursor Cell Lymphoblastic Leukemia-Lymphoma
222
Hematologic Neoplasms
212
Urinary Bladder Neoplasms
211
Uterine Cervical Neoplasms
200
Endometrial Neoplasms
199
Sarcoma
195
Glioma
194
Lymphoma, Non-Hodgkin
188
Interventions
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Exanthema
×
90 days
×
Clear all
NCT06399029
2026-04-30
TRUX-LST
University of Zurich
Phase 2
Active not recruiting
22 enrolled
NCT07476807
2026-04-28
TREATS
Sligo General Hospital
Phase NA
Enrolling by invitation
25 enrolled